‘Prime and Spike’ Nasal Vaccine Strategy Helps Combat COVID
The new “prime” and “spike” approach may help prevent breakthrough infections of vaccinated individuals by bolstering immune response within the mucosal lining of the respiratory tract, which are the first cells attacked by COVID-19.Source: YaleNews
Women's Health in the Time of COVID-19 Webinar
Uncovering how the coronavirus affects the biology of women and men differently is teaching us new ways to fight COVID-19. Identifying how the stress of the pandemic is different for women and men is focusing mental health professionals on risk and resilience. Watch Women’s Health Research at Yale Director Carolyn M. Mazure, Ph.D, and leading immunologist Akiko Iwasaki, Ph.D., in conversation with Yale Medalist Susanna Krentz, '80, as they discuss a major new research finding and next steps in investigating sex differences to advance the health of women and men.
Why Is COVID-19 Striking Men Harder Than Women?
Women's Health Research at Yale Director Carolyn M. Mazure and Immunobiology Professor Akiko Iwasaki, discuss how understanding why men suffer more severe cases of COVID-19 and are more likely to die is vital for developing effective strategies that can produce better outcomes for everyone.Source: Time
Yale Scientists Breach Brain Barriers to Attack Tumors
The brain is a sort of fortress, equipped with barriers designed to keep out dangerous pathogens. But protection comes at a cost: These barriers interfere with the immune system when faced with dire threats such glioblastoma, a deadly brain tumor for which there are few effective treatments.
Iwasaki Is Honored by the International Cytokine & Interferon Society
Akiko Iwasaki, PhD, Waldemar Von Zedtwitz Profesor of Immunobiology and Molecular, Cellular, and Developmental Biology; and professor of dermatology, is a 2019 recipient of the Seymour & Vivian Milstein Award for Excellence in Interferon and Cytokine Research, given by the International Cytokine & Interferon Society (ICIS).
New cancer immunotherapy drugs rapidly reach patients after approval
The majority of patients eligible for cancer immunotherapy drugs known as checkpoint inhibitors received treatment within a few months of FDA approval, according to a new Yale-led study. The finding suggests that cancer immunotherapies are adopted at a much quicker pace than is typical for newly approved medical treatments, the researchers said. However, patients receiving the therapies are older than those in the clinical trials used to evaluate them, pointing to a disconnect between research and practice that should be addressed, they noted.
Four Faculty Members Elected to the National Academy of Sciences
In recognition of their outstanding research achievements, four faculty members from the School of Medicine have been elected to the National Academy of Sciences (NAS). Akiko Iwasaki, PhD; Haifan Lin, PhD; David G. Schatz, PhD; and Günter Paul Wagner, PhD, were selected for one of the world’s highest honors that can be bestowed on a scientist.
Study: Topical antibiotic triggers unexpected antiviral response
A Yale-led research team made a startling discovery while investigating the effect of bacteria on viral infections. When they applied a common topical antibiotic to mice before or shortly after infection with herpes and other viruses, they found that the antibiotic triggered an antiviral resistance in the animals, the researchers said.
Study points to potential personalized approach to treating lupus
In individuals with lupus, immune cells attack the body’s own tissue and organs as if they are enemy invaders. A new Yale-led study describes how a protein found in common bacteria triggers that auto-immune response. The finding opens the door to future therapies targeting the bacteria rather than the immune system, the researchers said.